Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,489
archived clinical trials in
Endometrial Cancer

Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated:  9/28/2017
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated: 9/28/2017
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Click here to add this to my saved trials
Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated:  9/28/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Lymph Node Mapping in Patients With Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging
Status: Enrolling
Updated: 9/28/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated:  12/3/2017
Park Nicollet Cancer Center
mi
from
Saint Louis Park, MN
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated: 12/3/2017
Park Nicollet Cancer Center
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated:  12/3/2017
Crozer-Chester Medical Center
mi
from
Upland, PA
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated: 12/3/2017
Crozer-Chester Medical Center
mi
from
Upland, PA
Click here to add this to my saved trials
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Racial Disparity in Endometrial Cancer
Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer
Status: Enrolling
Updated:  1/5/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Racial Disparity in Endometrial Cancer
Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer
Status: Enrolling
Updated: 1/5/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Rush University Medical Center
mi
from
Chicago, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
The Hartford Hospital
mi
from
Hartford, CT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Memorial University Medical Center
mi
from
Savannah, GA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Memorial Medical Center
mi
from
Springfield, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Cox Medical Center South
mi
from
Springfield, MO
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Abington Memorial Hospital
mi
from
Abington, PA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Women and Infants Hospital
mi
from
Providence, RI
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Saint Francis Hospital
mi
from
Greenville, SC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Saint Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Biomarkers for Gynecologic Cancer
Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population
Status: Enrolling
Updated:  1/29/2018
Ohio State University
mi
from
Columbus, OH
Biomarkers for Gynecologic Cancer
Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population
Status: Enrolling
Updated: 1/29/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Beebe Medical Center
mi
from
Lewes, DE
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials